In 2023, the number of multidrug-resistant tuberculosis (MDR-TB) cases started on treatment in China stood at approximately 15.52 thousand. From 2024 onward, forecasts suggest a steady year-on-year increase: 2024 sees a 4.7% rise, followed by 4.5% in 2025, 4.3% in 2026, and 4.0% in 2027 and 2028. The compound annual growth rate (CAGR) over this period is about 4.3%, signaling a consistent upward trend.
Future trends to watch for:
- Improved access to and development of healthcare services might impact treatment initiation numbers.
- Innovations in diagnostic tools and drug efficacy could alter MDR-TB management efficiency.
- Policy changes and international collaborations could influence treatment strategies and access.
